Abstract 1455P
Background
Nivo as monotherapy for the treatment of aNSCLC after prior chemotherapy (chemo) was approved by EMA in 2015 and has been used in clinical practice since. In this study, we describe RW survival outcomes of patients with aNSCLC who resumed nivo after interrupting an initial nivo treatment received as 2+ line-of-therapy (LOT).
Methods
This study leverages RWD collected in 2 prospective, non-interventional studies: EVIDENS (NCT03382496; France) and ENLARGE (NCT02910999; Germany) on patients with aNSCLC treated with nivo. Data were pooled and two cohorts were defined: 1) nivo resumption cohort (patients who re-started nivo after an interruption of ≥6 weeks) and 2) chemo cohort (patients who received chemo or other systemic anti-cancer therapy after nivo). Demographics and clinical characteristics were described, and overall survival (OS) was estimated using Kaplan-Meier methods from the start of the “index treatment” (LOT following the initial nivo treatment).
Results
Among 2,266 patients (1,397 from France and 869 from Germany), 210 (9.3%) resumed nivo after an initial interruption of ≥6 weeks. 697 (30.8%) started a chemo treatment after nivo, among which 171 - from the ENLARGE study - had data required for this analysis and constituted the chemo cohort. Median age was 67 (range: 41-89) in the nivo resumption cohort and 64 (21-83) in the chemo cohort. In both cohorts, majority of patients were male and received their index treatment as third LOT. Median OS was 19.6 months (mo) [95% CI: 16.2-25.2] for the nivo resumption cohort and 9.1 mo [7.1-10.0] for the chemo cohort. Nivo-resuming patients who had received an initial nivo treatment of ≥3 mo had a median OS of 22.8 mo, compared to 10.7 mo in patients with <3 mo initial nivo treatment. In the chemo cohort, patients with a duration of initial nivo therapy of ≥3 mo had a median OS of 9.9 mo in subsequent treatment, compared with 7.1 mo in patients with <3 mo of initial nivo treatment.
Conclusions
OS data show that patients with aNSCLC who interrupted their initial nivo treatment may benefit from resuming nivo, primarily when initial exposure to nivo lasted for more than three months.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Bristol Myers Squibb.
Funding
Bristol Myers Squibb.
Disclosure
M. Pérol: Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, MSD, BMS, Lilly, Novartis, Takeda, Gritstone, Sanofi, Pfizer, Amgen, Janssen, GSK, Eisai, Ipsen; Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, MSD, BMS, Boehringer Ingelheim, Takeda, Illumina, Pfizer, Medscape; Financial Interests, Institutional, Research Grant: AstraZeneca, Roche, Takeda, Boehringer Ingelheim; Financial Interests, Personal, Steering Committee Member: Roche; Financial Interests, Personal, Other, DMSB: Roche. M. Sebastian: Financial Interests, Personal, Other, Honoraria: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Janssen Oncology, Lilly, MSD, Novartis, Pfizer/EMD Serono, Roche/Genentech, Sanofi, Takeda; Financial Interests, Personal, Advisory Role: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Janssen Oncology, Lilly, MSD, Novartis, Pfizer, Roche/Genentech, Sanofi, Takeda; Financial Interests, Institutional, Research Funding: AstraZeneca; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Pfizer, Takeda. F. Barlesi: Financial Interests, Institutional, Advisory Board: AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd, Novartis, Merck, Mirati, MSD, Pierre Fabre, Pfizer, Sanofi Aventis, Seattle Genetics, Takeda, AbbVie, Acea, Amgen, Eisai, Ignyta; Non-Financial Interests, Principal Investigator: AstraZeneca, BMS, Merck, Pierre Fabre, F. Hoffmann-La Roche Ltd., Innate Pharma, Mirati. C. Schumann: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, MSD; Financial Interests, Institutional, Advisory Board: AstraZeneca; Financial Interests, Personal, Writing Engagement: AstraZeneca; Financial Interests, Personal, Advisory Board: BMS, Roche; Financial Interests, Institutional, Invited Speaker: Lilly. D. Reynaud, D. Waldenberger, A. Lee, N. Varol, J.R. Penrod, F. Brellier: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb; Financial Interests, Personal, Stocks/Shares: Bristol Myers Squibb.
Resources from the same session
1390P - Real-world characteristics, treatment patterns and outcomes of patients with advanced HER2/ERBB2-mutant non-small cell lung cancer (NSCLC) in France and Germany
Presenter: Petros Christopoulos
Session: Poster session 20
1391P - Capmatinib vs docetaxel as second- or third-line (2/3L) therapy in patients (pts) with METex14-mutated advanced NSCLC (aNSCLC): The GeoMETry-III trial
Presenter: Oscar Jose Juan Vidal
Session: Poster session 20
1392P - Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP)
Presenter: Karlijn Verkerk
Session: Poster session 20
1393P - Characteristics of MET gene and its relationship with TMB/MMR genes in Chinese NSCLC population
Presenter: Hong Yi Zhang
Session: Poster session 20
1394P - Real-world experience in treatment of patients with non-small cell lung cancer with BRAF and cMET Exon 14 skipping mutations
Presenter: Urska Janzic
Session: Poster session 20
1396P - HER2 testing pattern, characteristics of locally advanced or metastatic NSCLC patients by HER2 testing in France
Presenter: Didier Debieuvre
Session: Poster session 20
1397P - Prevalence, molecular characterization, and prognosis of MET–overexpressing non-small cell lung cancer (NSCLC) in a real-world patient cohort
Presenter: Jair Bar
Session: Poster session 20
1398P - Hepatotoxicity in patients (pts) with KRASG12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib after prior immunotherapy (IO)
Presenter: Sophie Ernst
Session: Poster session 20
1399P - Tumor-immune microenvironment analysis of de novo and acquired KRAS-mutated non-small cell lung cancer
Presenter: Joshua Reuss
Session: Poster session 20
1400P - Real-world effectiveness and safety of sotorasib in patients with KRAS G12C mutated metastatic non-small cell lung cancer (NSCLC): Results of the IFCT-2102 Lung KG12Ci study
Presenter: Marie Wislez
Session: Poster session 20